Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 86-92

  Rosenblat, Mira ^a   Volkova, Nina ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cholesterol; Macrophages; Oxidative stress; Paraoxonase 1; Paraoxonase 2; Pomegranate juice; Triglycerides

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; CHOLESTEROL; GALLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POMEGRANATE EXTRACT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; KNOCKOUT MOUSE; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; POMEGRANATE JUICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BEVERAGES; CHOLESTEROL; FRUIT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PUNICACEAE; RNA, MESSENGER; SUPEROXIDES; TRIGLYCERIDES; UP-REGULATION;

EID: 77956231001     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.039     Document Type: Article

References (39)

1. Tiwari R.L., Singh Y., Barthwal M.K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008, 28:483-544.
2. Lusis A.J. Atherosclerosis. Nature 2000, 404:233-241.
3. Mattsson L., Johansson H., Ottosson M., Bondjers G., Wilklund O. Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta. J Clin Invest 1993, 92:1759-1765.
4. Aviram M., Rosenblat M. Paraoxonases 1, 2 and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Chem 2004, 37:1304-1316.
5. Rosenblat M., Coleman R., Reddy S.T., Aviram M. Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1. J Lipid Res 2009, 50:870-879.
6. Meilin E., Aviram M., Hayek T. Paraoxonase 2 (PON2) decreases high glucose-induced macrophage triglycerides (TG) accumulation, via inhibition of NADPH-oxidase and DGAT1 activity: studies in PON2-deficient mice. Atherosclerosis 2010, 208:390-395.
7. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005, 46:1239-1247.
8. Gaidukov L., Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005, 44:11843-11854.
9. Ng C.J., Wadleigh D.J., Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001, 76:44444-44449.
10. Rosenblat M., Draganov D., Watson C.E., Bisgaier C.L., La Du B.N., Aviram M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:468-474.
11. Rosenblat M., Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009, 35:98-104.
12. Efrat M., Aviram M. Macrophage paraoxonase 1 (PON1) binding sites. Biochem Biophys Res Commun 2008, 376:105-110.
13. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
14. Rozenberg O., Shih D.M., Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003, 23:461-467.
15. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006, 281:7657-7665.
16. Horke S., Witte I., Wilgenbus P., Krüger M., Strand D., Förstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007, 115:2055-2064.
17. Basu A., Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev 2009, 67:49-56.
18. Tzulker R., Glazer I., Bar-Ilan I., Holland D., Aviram M., Amir R. Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J Agric Food Chem 2007, 55:9559-9570.
19. Aviram M., Dornfeld L., Rosenblat M., et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000, 71:1062-1076.
20. Aviram M., Rosenblat M., Gaitini D., et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004, 23:423-433.
21. Davidson M.H., Maki K.C., Dicklin M.R., et al. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol 2009, 104:936-942.
22. Rosenblat M., Hayek T., Aviram M. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 2006, 187:363-371.
23. Rock W., Rosenblat M., Miller-Lotan R., Levy A.P., Elias M., Aviram M. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008, 56:8704-8713.
24. Kaplan M., Hayek T., Raz A., et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001, 131:2082-2089.
25. Fuhrman B., Volkova N., Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem 2005, 16:570-576.
26. Shiner M., Fuhrman B., Aviram M. Macrophage paraoxonase 2 (PON2) expressions is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation. Atherosclerosis 2007, 195:313-321.
27. Khateeb J., Gantman A., Kreitenberg A.J., Aviram M., Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis 2010, 208:119-125.
28. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003, 34:774-784.
29. Ng C.J., Bourquard N., Grijalva V., et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 2006, 281:29491-29500.
30. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 1983, 30:111-118.
31. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
32. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 1978, 52:302-310.
33. - secreted by monocytes and macrophages. Methods Enzymol 1984, 105:365-369.
34. Bass D.A., Parce J.W., Dechatelet L.R., Szejda P., Seeds M.C., Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol 1983, 130:1910-1917.
35. 3H] cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J Biol Chem 2000, 275:29939-30001.
36. Aviram M., Rosenblat M., Etzioni A., Levy R. Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism 1996, 45:1069-1079.
37. Farese R.V., Cases S., Smith S.J. Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. Curr Opin Lipidol 2000, 11:229-234.
38. Uto-Kondo H., Ayaori M., Ogura M., et al. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. Circ Res 2010, 106:779-787.
39. Aviram M., Volkova N., Coleman R., et al. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in-vivo in atherosclerotic apolipoprotein E-deficient (E 0) mice and in-vitro in cultured macrophages and lipoproteins. J Agric Food Chem 2008, 56:1148-1157.